Skip to main content
Fig. 1 | Stem Cell Research & Therapy

Fig. 1

From: A novel MSC-based immune induction strategy for ABO-incompatible liver transplantation: a phase I/II randomized, open-label, controlled trial

Fig. 1

Study flow chart. Enrolment, randomization, and follow-up of patients in the MSCs and rituximab trial. Between August 2016 and August 2018, a total of 47 severe hepatic failure patients receiving ABO-i LT were screened. Twenty-two participants were enrolled in the present study and were randomly divided into 2 groups (MSC group = 11, rituximab group = 11). Finally, 11 participants in the MSC group and 11 in the rituximab group completed the follow-up and were included in the analysis

Back to article page

Stem Cell Research & Therapy

ISSN: 1757-6512